Cargando…

Checkpoint and PARP inhibitors, for whom and when

Detalles Bibliográficos
Autores principales:	Lee, Jung-Min, Gulley, James L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707002/ https://www.ncbi.nlm.nih.gov/pubmed/29221108 http://dx.doi.org/10.18632/oncotarget.20852

Ejemplares similares

In search of the optimal proteosome inhibitor. How, when and for whom?
por: Engelhardt, Monika, et al.
Publicado: (2021)

To immunosuppress: whom, when and how? That is the question with COVID-19
por: Winthrop, Kevin L, et al.
Publicado: (2020)

Pediatric Percutaneous Endoscopic Gastrostomy in Korea - When? By Whom? How?
por: Lee, Yoon
Publicado: (2022)

Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis
por: Gatti-Mays, Margaret, et al.
Publicado: (2021)

PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016)

PSA screening – for whom and when?
por: Albers, Peter
Publicado: (2019)

Bempedoic Acid: for Whom and When
por: Ruscica, Massimiliano, et al.
Publicado: (2022)

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
por: Wu, Zhaozhen, et al.
Publicado: (2021)

Unguided De-Escalation Strategy From Potent P2Y(12) Inhibitors in Patients Presented With ACS: When, Whom and How?
por: Park, Jin Sup, et al.
Publicado: (2022)

The future … to whom it belongs?()
por: Abrahão, Marcio
Publicado: (2016)

To Whom It May Concern
Publicado: (1888)

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?
por: Atallah, Ehab, et al.
Publicado: (2020)

Freeze-all, for whom, when, and how
por: Celada, Paula, et al.
Publicado: (2020)

Credit to Whom Credit Is Due
Publicado: (1871)

Credit to Whom Credit Is Due
Publicado: (1853)

Credit to Whom Credit Is Due
Publicado: (1855)

To Whom Belongs the Honor of Discovery?
Publicado: (1893)

Credit to Whom Credit Is Due
Publicado: (1888)

Credit to Whom Credit Is Due
Publicado: (1883)

PARP inhibitors, use early in the first-line maintenance therapy setting but with caution
por: Giudice, Elena, et al.
Publicado: (2023)

The when, why and whom to biopsy of type 1 diabetes mellitus children with positive anti-tissue transglutaminase serology
por: Guandalini, Stefano
Publicado: (2023)

Emergency airway management – by whom and how?
por: Sollid, S. J. M., et al.
Publicado: (2016)

Whom to further monitor in remote monitoring?
por: Barake, Walid, et al.
Publicado: (2019)

Oncoplastic Breast Surgery: What, When and for Whom?
por: Macmillan, R. Douglas, et al.
Publicado: (2016)

COVID-19 patients: when and whom to ventilate?
por: Lal, Tusharindra, et al.
Publicado: (2020)

Radiotherapy in Pancreatic Cancer: To Whom, When, and How?
por: Falco, Michał, et al.
Publicado: (2023)

PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer
por: Curtin, Nicola, et al.
Publicado: (2020)

Maintenance of Certification – important and to whom?
por: Kempen, Paul M.
Publicado: (2013)

Honour to Whom Honour Is Due
Publicado: (1872)

Disentangling what works best for whom in comorbidity
por: Glozier, Nick, et al.
Publicado: (2022)

Medical Teaching: Credit to Whom Credit Is Due
Publicado: (1873)

Combining enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness
por: Thompson, Timothy C., et al.
Publicado: (2017)

PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
por: Frizzell, Kristine M, et al.
Publicado: (2009)

Salvage radiotherapy with or without hormone therapy: for whom and when?
por: Carrie, Christian
Publicado: (2017)

Laparoscopy in Blunt Abdominal Trauma: for Whom? When?and Why?
por: Justin, Viktor, et al.
Publicado: (2017)

Non-invasive ventilation in the ED: Whom, When, How?
por: Göksu, Erkan, et al.
Publicado: (2018)

Severe Asthma and Biological Therapy: When, Which, and for Whom
por: Rogliani, Paola, et al.
Publicado: (2019)

Capsule Endoscopy in Inflammatory Bowel Disease: When? To Whom?
por: Na, Soo-Young, et al.
Publicado: (2021)

Genetic testing in focal segmental glomerulosclerosis: in whom and when?
por: Tato, Ana María, et al.
Publicado: (2023)

Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
por: Revythis, Antonios, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_led35qa38468qg71ge0v72gdm3